PMID- 25318790
OWN - NLM
STAT- MEDLINE
DCOM- 20150615
LR  - 20190606
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Linking)
VI  - 53
IP  - 20
DP  - 2014
TI  - Experience with seven Japanese patients with antineutrophil cytoplasmic 
      antibody-associated vasculitis treated with remission-induction therapy with 
      intravenous cyclophosphamide according to the CYCLOPS protocol.
PG  - 2291-6
AB  - OBJECTIVE: In 2009, the European Vasculitis Study Group reported the results of 
      CYCLOPS, a randomized controlled trial, in which pulse cyclophosphamide (CYC) was 
      found to be similar to a daily CYC regimen in inducing remission in patients with 
      antineutrophil cytoplasmic antibody-associated vasculitis (AAV). We herein 
      conducted an observational study to describe our experience with Japanese AAV 
      patients treated with pulse CYC according to the CYCLOPS protocol. METHODS: The 
      inclusion criteria were as follows: 1) granulomatosis with polyangiitis, of 
      either the limited or generalized type; 2) microscopic polyangiitis or renal 
      limited glomerulonephritis with at least one poor prognostic factor; or 3) 
      microscopic polyangiitis with a motor disturbance due to vasculitic neuropathy. 
      The patients were treated with pulse cyclophosphamide and prednisolone according 
      to the CYCLOPS protocol. RESULTS: Seven patients were included, all of whom 
      (100%) achieved remission with a median time to remission of three months. After 
      the first remission, two patients experienced relapse during the follow-up period 
      of 14.8 months and both were successfully treated with additional pulse CYC 
      therapy. Regarding safety, infection was observed in all patients, including 
      three patients with respiratory tract infections, although all infectious 
      episodes were successfully treated. Bronchoalveolar carcinoma was diagnosed in 
      one patient. CONCLUSION: The administration of pulse CYC according to the CYCLOPS 
      protocol was found to be effective as remission induction therapy in our seven 
      patients with AAV. With regard to safety, treating Japanese patients with AAV 
      according to this protocol may require close attention for signs of respiratory 
      infection. Our findings suggest that this protocol is therefore a viable option 
      for Japanese patients with AAV.
FAU - Oiwa, Hiroshi
AU  - Oiwa H
AD  - Department of Rheumatology, Hiroshima City Hospital, Japan.
FAU - Yamasaki, Satoshi
AU  - Yamasaki S
FAU - Endo, Koji
AU  - Endo K
FAU - Nojima, Takaki
AU  - Nojima T
FAU - Kumagai, Kazuhiko
AU  - Kumagai K
FAU - Sugiyama, Eiji
AU  - Sugiyama E
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20141015
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 (Immunosuppressive Agents)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - 9PHQ9Y1OLM (Prednisolone)
SB  - IM
MH  - Administration, Intravenous
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*drug therapy
MH  - Cyclophosphamide/*administration & dosage
MH  - Female
MH  - Glomerulonephritis/drug therapy
MH  - Granulomatosis with Polyangiitis/drug therapy
MH  - Humans
MH  - Immunosuppressive Agents/*administration & dosage
MH  - Male
MH  - Microscopic Polyangiitis/drug therapy
MH  - Middle Aged
MH  - Prednisolone/therapeutic use
MH  - Pulse Therapy, Drug
MH  - Remission Induction
MH  - Retrospective Studies
EDAT- 2014/10/17 06:00
MHDA- 2015/06/16 06:00
CRDT- 2014/10/17 06:00
PHST- 2014/10/17 06:00 [entrez]
PHST- 2014/10/17 06:00 [pubmed]
PHST- 2015/06/16 06:00 [medline]
AID - DN/JST.JSTAGE/internalmedicine/53.2553 [pii]
AID - 10.2169/internalmedicine.53.2553 [doi]
PST - ppublish
SO  - Intern Med. 2014;53(20):2291-6. doi: 10.2169/internalmedicine.53.2553. Epub 2014 
      Oct 15.